Immuno-Oncology

Mehra Details the Importance of PD-L1 Expression in HNSCC Treatment Selection

November 25, 2022

Ranee Mehra, MD, discusses the link between PD-L1 expression and increased immunotherapy efficacy in head and neck squamous cell carcinoma, and what future treatment options may look like for patients in this space.

Nurse-Led Research Links Saturate Fatty Acids to Improved Immunotherapy Responses in NSCLC

September 23, 2022

Julie Malo, CCRP, a research nurse with the University of Montreal, discusses a nurse-directed initiative examining how the gut microbiome affects immune checkpoint blockade responses in patients with non–small cell lung cancer.

Real-World HRQOL Findings Support Nivolumab for Previously Treated mRCC

September 19, 2022

Results of retrospective analysis of previously treated patients with metastatic renal cell carcinoma who received nivolumab in the second- and third-line showed that health-related quality of life was maintained in the real-world setting